Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H25N3O4S |
| Molecular Weight | 463.549 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=NN(CC2=CC=C(OCC3=CSC(=N3)C4=CC=CC=C4)C=C2)C=C1CCC(O)=O
InChI
InChIKey=SRFCAWATPLCLMG-UHFFFAOYSA-N
InChI=1S/C25H25N3O4S/c1-2-31-24-20(10-13-23(29)30)15-28(27-24)14-18-8-11-22(12-9-18)32-16-21-17-33-25(26-21)19-6-4-3-5-7-19/h3-9,11-12,15,17H,2,10,13-14,16H2,1H3,(H,29,30)
| Molecular Formula | C25H25N3O4S |
| Molecular Weight | 463.549 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sipoglitazar (TAK 654) was a novel, azolealkanoic acid derivative that possesses selective activity for the peroxisome proliferator-activated receptors (PPAR) PPARγ, PPARα, and PPARδ. Sipoglitazar was developed to improve
peripheral insulin sensitivity, normalize circulating lipid
profiles, and reduce body weight in patients with metabolic syndrome and type 2 diabetes mellitus (T2DM). Sipoglitazar was being developed by Takeda for the treatment of diabetes mellitus, however in September 2006, development was discontinued.
Originator
Approval Year
Sample Use Guides
In the ascending dose part of the study, 48 subjects
received one dose of placebo and two single doses of sipoglitazar at doses of 0.2, 0.4, 1, 2, 4, 8, 16, 32, and 64 mg. In male subjects, single oral doses of sipoglitazar, 0.2–64 mg, were well tolerated, as were single oral doses of 16–64 mg in female subjects.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:41:56 UTC 2023
by
admin
on
Fri Dec 15 17:41:56 UTC 2023
|
| Record UNII |
40O898CJZB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98233
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8610
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
PRIMARY | |||
|
C87622
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
PRIMARY | |||
|
40O898CJZB
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
PRIMARY | |||
|
300000034314
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
PRIMARY | |||
|
CHEMBL2107780
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
PRIMARY | |||
|
9825652
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
PRIMARY | |||
|
342026-92-0
Created by
admin on Fri Dec 15 17:41:56 UTC 2023 , Edited by admin on Fri Dec 15 17:41:56 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
MINOR
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
MAJOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
